This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include GSK’s $50M partnership with LTZ for myeloid cell engagers, Kind Pharma’s RMB 400M+ Series C for anemia and breast cancer programs, and Phrontline’s $60M funding to advance bispecific ADCs. Clinical breakthroughs feature BeOne’s zanidatamab + tislelizumab combo significantly improving survival in HER2+ GEA, Sichuan Biokin’s iza-bren meeting PFS/OS endpoints in esophageal cancer, and Kangpu’s KPG-818 achieving 50% ORR in r/r MM. Additionally, YolTech secured FDA IND clearance for YOLT-203, a gene-editing therapy for PH1; Abbisko’s pimicotinib reached 76.2% ORR in TGCT; and Innovent’s mazdutide demonstrated up to 20.1% weight loss in obesity, with NDA filing underway.
